Boehringer Ingelheim plans to invest €17 million in its biopharmaceutical drug development and manufacturing capabilities in Europe.
The expansion of its facilities in Biberach, Germany, and Vienna, Austria, will reinforce Boehringer’s position as the industry’s leading contract manufacturer.
By investing in cell culture and microbial technologies for drug development, Boehringer will also strengthen its relationship with the biotech sector.
The new investment follows years of building the company’s capacity for contract manufacture of biopharmaceuticals through its cell culture facilities in Biberach and its microbial fermentation facility in Vienna.
The money will cover cell line and microbial strain development, as well as process development in contract drug manufacturing, and will be used to expand Boehringer’s Good Manufacturing Practice capabilities in these areas.
At the Biberach site, the investment will support the company’s ‘Lean to Clinic’ programme for monoclonal antibody projects, aiming to deliver drug candidates ready for clinical testing within 13 months.
At the Vienna site, it will advance Boehringer’s proprietary technologies, including its plasmid DNA manufacturing platform and its biotech collaborations with Pfenex and VTU Technology.
“The expansion has been tailor-suited to fully meet our customer demands in cell culture and microbial process science, especially for our rapidly expanding preclinical project portfolio with biotech companies,” said Dr Dorothee Ambrosius, Boehringer’s Senior VP for Biopharmaceuticals Global Process Science.
“This is another milestone within our contract manufacturing strategy, securing technology leadership and towards increased flexibility and customer orientation.”
Boehringer accounts for 23% of contract manufacturing capacity in the global biopharmaceuticals sector.